OriCiro Genomics K.K. is a company that specializes in cell-free DNA synthesis and amplification technologies, according to a Jan. 4 Moderna news release.
“With this acquisition, we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing,” Stéphane Bancel, CEO of Moderna, said in the release. “OriCiro’s technology strategically complements our manufacturing expertise and further accelerates our research and development engine.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
